According to the Zhitong Finance APP, INT MEDICAL (01501) announced that on October 10, 2025 (after trading hours), the company entered into a subscription agreement with BRONCUS, under which BRONCUS conditionally agreed to issue a total of 91,093,613 subscription shares to the company at a subscription price of HKD 3.11 per subscription share, for a total consideration of HKD 283,301,136.43 (excluding transaction costs), subject to the terms and conditions set forth in the subscription agreement.
Upon completion, the company will hold a total of 91,093,613 shares of BRONCUS, which will represent approximately 17.24% of the issued shares of BRONCUS as of the date of this announcement (approximately 17.30% if treasury shares are not counted) and approximately 14.38% of the expanded issued shares of BRONCUS due to this issuance of subscription shares (approximately 14.42% if treasury shares are not counted). The financial performance of BRONCUS will not be consolidated into the group's accounts.
The announcement stated that considering BRONCUS's rich product line in the non-vascular intervention field, the subscription matter could further expand the company's strategic layout in the non-vascular intervention field

02216

01501

INT MEDICAL plans to subscribe for approximately 91.0936 million shares of BRONCUS-B at a price of HKD 3.11 per share, totaling around HKD 283 million. Upon completion, INT MEDICAL will hold approximately 17.24% of the shares of BRONCUS-B. This subscription will assist INT MEDICAL in its strategic layout in the non-vascular intervention field

INT MEDICAL plans to invest approximately HKD 283 million to subscribe for about 91.0936 million shares of BRONCUS-B